To the Editor—We appreciate that Redd et al [1] discuss elevated microbial translocation in advanced human immunodeficiency virus (HIV) disease, as has been reported by us and others [2–5]. We agree with them that longitudinal studies are important to clarify causal relationships between microbial translocation and disease progression. Thus, we wrote, “Further studies on the impact of microbial translocation during the follow-up of HIV-1 and HIV-2 infection disease courses may reveal important implications for the clinical outcome of HIV-infected individuals” [2]. Longitudinal studies comparing the disease course of HIV-1– and HIV-2–infected individuals within the same cohort or geographic area would optimally include individuals with known time for infection, because both infections display highly variable rates of disease progression. This would require access to samples stored in optimal conditions over extended periods, which is a challenging task in settings where these infections circulate. From our own report it is, however, clear that lipopolysaccharide (LPS) levels in plasma of individuals with chronic HIV-1 or HIV-2 infection without signs or symptoms of AIDS are not elevated when compared with HIV-negative individuals [2]. Thus, detectable elevation of plasma LPS levels appears to be restricted to advanced disease, suggesting that disease progression plays a role in the triggering of microbial translocation. However, it may well be that once microbial translocation arises, it contributes to acceleration of disease progression during the advanced disease phase. Intriguingly, we also found elevated plasma LPS levels in HIV-2–infected persons with severe immunodeficiency (CD4+ T cell count, <200 /μL), despite the fact that the median plasma viral load in HIV-2–infected individuals is at least 1 log lower than that in HIV-1–infected persons matched for CD4+ T cell count [2, 6, 7]. Accordingly, viremia may not be the sole determinant for induction of microbial translocation, and we look forward to further studies on this important topic.
References
- 1.Redd AD, Gray RH, Quinn TC. Microbial translocation a cause or consequence of HIV disease progression? J Infect Dis. doi: 10.1093/infdis/jiq107. doi: 10.1093/jid/jiq107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Nowroozalizadeh S, Månsson F, da Silva Z, et al. Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections. J Infect Dis. 2010;201:1150–4. doi: 10.1086/651430. [DOI] [PubMed] [Google Scholar]
- 3.Cassol E, Malfeld S, Mahasha P, et al. Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J Infect Dis. 2010;202:723–33. doi: 10.1086/655229. [DOI] [PubMed] [Google Scholar]
- 4.Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One. 2008;3:e2516. doi: 10.1371/journal.pone.0002516. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–71. doi: 10.1038/nm1511. [DOI] [PubMed] [Google Scholar]
- 6.Nowroozalizadeh S, Månsson F, da Silva Z, et al. Studies on Toll-like receptor stimuli responsiveness in HIV-1 and HIV-2 infections. Cytokine. 2009;46:325–31. doi: 10.1016/j.cyto.2009.03.003. [DOI] [PubMed] [Google Scholar]
- 7.Andersson S, Norrgren H, da Silva Z, et al. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: Significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch Intern Med. 2000;160:3286–93. doi: 10.1001/archinte.160.21.3286. [DOI] [PubMed] [Google Scholar]